Active Ingredient(s): Dexmethylphenidate Hydrochloride + Serdexmethylphenidate Chloride
FDA Approved: * March 2, 2021
Pharm Company: * COMMAVE THERAP
Category: ADD / ADHD

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Azstarys Overview

Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older.[2] It was approved for medical use in the United States in March 2021.[2] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-st...

Read more Azstarys Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Azstarys Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dexmethylphenidate Hydrochloride + Serdexmethylphenidate Chloride
  • Capsule: 10.4mg + 52.3mg, 5.2mg + 26.1mg, 7.8mg + 39.2mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Azstarys: (3 results)

Sorted by National Drug Code
  • 65038-286 Azstarys Oral Capsule by Corium, Inc
  • 65038-429 Azstarys Oral Capsule by Corium, Inc
  • 65038-561 Azstarys Oral Capsule by Corium, Inc

Drugs with one or more similar ingredients: (2 results)